ANIK

Anika Therapeutics Inc.

22.62 USD

Last updated Dec 10, 07:42 UTC

Yesterday HIGH

$22.98

Yesterday LOW

$22.23

52w HIGH

$32.33

52w LOW

$16.54

EPS

0

PE

0.00

Next Earnings

Mar 4, 2024

Overview News Government Trades

Anika Therapeutics Inc. stock is up 12.99% since 30 days ago. The next earnings date is Mar 4, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 29 December’s closed higher than November.

Anika Therapeutics, Inc. creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Medical Equipment

Headquarters

Bedford, United States Of America

Website

anikatherapeutics.com

Benzinga Insights

Tue May 9, 2023

Earnings Scheduled For May 9, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.
richadhand@benzinga.com

Fri Apr 14, 2023

Stephens & Co. Reiterates Equal-Weight on Anika Therapeutics, Maintains $28 Price Target

Stephens & Co. analyst George Sellers reiterates Anika Therapeutics (NASDAQ:ANIK) with a Equal-Weight and maintains $28 price target.
Michael Horton

Thu Apr 13, 2023

Anika Enters Into Cooperation Agreement With Caligan Partners; Board Authorized $20M Share Repurchase Program
Happy Mohamed

Mon Apr 3, 2023

Anika Continues To Expand Addressable Market For Tactoset Injectable Bone Substitute With Additional 510(k) Clearance From FDA

Tactoset cleared by the FDA to be combined with autologous bone marrow aspirate, a core element for regenerative healing Anika reaches agreement to distribute the Marrow Cellution™ Bone Marrow Aspiration
Happy Mohamed

Mon Mar 27, 2023

Anika Files Preliminary Proxy Statement In Connection With Its Upcoming 2023 Annual Meeting Of Stockholders

Anika Therapeutics, Inc. (NASDAQ:ANIK) ("Anika" or the "Company"), a global joint preservation company in early intervention orthopedics, today announced that it has filed its preliminary proxy
Benzinga Insights

Tue Mar 7, 2023

Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
richadhand@benzinga.com

Tue Mar 7, 2023

Barrington Research Downgrades Anika Therapeutics to Market Perform

Barrington Research analyst Michael Petusky downgrades Anika Therapeutics (NASDAQ:ANIK) from Outperform to Market Perform.
Benzinga Newsdesk

Mon Mar 6, 2023

Anika Therapeutics Sees FY23 Revenue $158M-$163M vs $168.4M Est.
Benzinga Newsdesk

Mon Mar 6, 2023

Anika Therapeutics Q4 Adj. EPS $(0.21) Beats $(0.24) Estimate, Sales $39.60M Beat $37.70M Estimate

Anika Therapeutics (NASDAQ:ANIK) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.24) by 12.5 percent. This is a 8.7 percent increase over losses of $(0.23) per share from
Benzinga Insights

Mon Mar 6, 2023

Earnings Scheduled For March 6, 2023

Companies Reporting Before The Bell • Passage Bio (NASDAQ:PASG) is estimated to report earnings for its fourth quarter.